MODERN ASPECTS OF TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION WITH NEW ORAL ANTICOAGULANTS
The review article describes current aspects of the use of new oral anticoagulants in patients with AF. Weaknesses and strengths of anticoagulants are considered. The questions of anticoagulants administration to patients with valvular and non-valvular atrial fibrillation are considered. Particular attention is paid to stratifying the risk of thromboembolism in atrial fibrillation. A comparison of new oral anticoagulants and warfarin is given. Modern new oral anticoagulants registered in the Russian Federation are described. The features of the use of drugs in patients with liver pathology, acute coronary syndrome, and renal failure are considered. Aspects of administration of new oral anticoagulants in patients with atrial fibrillation during cardioversion are considered. The principles of transferring patients from one anticoagulant to another are considered. The provided approaches can help practitioners in choosing the most acceptable and rational management scheme for a patient with AF.
Vishnevskij V.I., Panina Ju.N. 2019. Modern aspects of treatment of patients with atrial fibrillation with new oral anticoagulants. Challenges in Modern Medicine, 43(1): 65–72 (in Russian). DOI
While nobody left any comments to this publication.
You can be first.
1. Bokarev I.N., Kondrat'eva T.B. 2016. Novye oral'nye antikoaguljanty v klinichskoj praktike. Jeffektivnost' i problemy [New oral anticoagulants in medicine practice. Efficiency and problems]. Klinicheskaja medicina. 94 (5): 383–387.
2. Bokerija L.A. 2005. Profilaktika insul'ta pri fibrilljacii predserdij [Prevention of stroke on pa-tients with atrial fibrillation]. Annaly aritmologii. 3: 45–55.
3. Bokerija O.L., Kopaliani T.I. 2016. Otkazhemsja li my ot varfarina? [Can we refuse of warfa-rin?] Annaly aritmologii. 13 (2): 87–95.
4. Galjavich A.S. 2012. Sovremennye podhody k profilaktike insul'tov pri fibrilljacii predserdij. Novye tehnologii v medicine [Modern approaches of prevention of strokes with atrial fibrillation. New technologies in medicine]. Kardiologija. 5: 93–97.
5. Damulin I.V., Andreev D.A. 2015. Fibrilljacija predserdij [Atrial fibrillation]. Rossijskij medicinskij zhurnal. 6: 41–45.
6. Efremova O.A., Kletkina A.S., Kamyshnikova L.A., Beljaeva S.S. 2013. Primenenie antiko-aguljantov u bol'nyh s fibrilljaciej predserdij i porokami serdca [Analysis of therapy with anticoagulants in patients who have malformations of the heart and atrial fibrillation]. Nauchnye vedomosti Belgo-rodskogo gosudarstvennogo universiteta. Serija: Medicina. Farmacija. 25 (168): 118–121.
7. Kanorskij S.G., Giljarevskij S.R. Tarasov A.V., Zhuk V.S., Javelov I.S. 2018. Novye rek-omendacii EHRA po antikoaguljantnoj terapii u bol'nyh s fibrilljaciej predserdij: kommentarii rossijskih jekspertov [New EHRA recommendations on anticoagulant therapy in patients with atrial fibrillation: comments of Russian experts]. Mezhdunarodnyj zhurnal serdca i sosudistyh zabolevanij. 6 (19): 45–56.
8. Kletkina A.S., Efremova O.A. 2014. Antitromboticheskaja terapija fibrilljacii predserdij [An-tithrombotic atrial fibrillation therapy]. Nauchnyj rezul'tat. Serija: Medicina i farmacija. 1 (1): 24–30.
9. Kobalova Zh.D., Shavrov A.A. 2018. Prakticheskie aspekty antikoaguljantnoj terapii dabigatranom u pacientov s fibrilljaciej predserdij i AG [Practical aspects of anticoagulant therapy with dabigatran in patients with atrial fibrillation and hypertension]. Kardiologija. 58: 42–55.
10. Marcevich S.Ju., Lukina Ju.V. 2017. Varfarin i ego znachenie v jeru novyh oral'nyh antiko-aguljantov. Voprosy kontrolja jeffektivnosti i bezopasnosti lechenija [Варфарин и его значение в эру новых оральных антикоагулянтов. Вопросы контроля эффективности и безопасности лечения]. Racional'naja Farmakoterapija v Kardiologii. 13: 699–705.
11. Novikova N.A., Volovchenko A.N. 2016. Varfarin: mesto v sovremennoj antikoaguljantnoj terapii [Warfarin: a place in modern anticoagulant therapy]. Specializirovannyj medicinskij zhurnal. 1: 50–58.
12. Nurasheva Je.E., Myrzagulova A.O., Tekebaeva L.A., Uteuliev E.S. 2017. Vozmozhnosti sov-remennoj antikoaguljantnoj terapii u pacientov s fibrilljaciej predserdij i ishemicheskim insul'tom [Possi-bilities of modern anticoagulant therapy in patients with atrial fibrillation and ischemic stroke]. Vestnik KazNMU. 4: 116–118.
13. Ostroumova O.D., Voevodina N.Ju., Pavleeva T.F., Piksina G.F., Goloborodova I.V. 2015. Profilaktika insul'ta u pacienta s fibrilljaciej predserdij i soputstvujushhimi zabolevanijami [Prevention of stroke in patients with atrial fibrillation and comorbidities]. Sistemnye gipertenzii. 15 (2): 55–59.
14. Storozhakov G.I., Borisov S.N., Gendlin G.E., Melehov A.V. 2013. Primenenie peroral'nyh antikoaguljantov pri fibrilljacii predserdij: sovremennoe sostojanie problemy i novye vozmozhnosti [The use of oral anticoagulants in atrial fibrillation: current state of the problem and new opportunities]. Arhiv vnutrennej mediciny. 2: 57–64.
15. Fonjakin A.V. 2014. Dabigatrana jeteksilat pri neklapannoj fibrilljacii predserdij v real'noj praktike i perspektivy ego primenenija dlja profilaktiki insul'ta [Dabigatran etexilate in non-valvular atrial fibrillation in real practice and prospects of its use for stroke prevention]. Nevrologija, nejropsihiatrija, psihosomatika. 6 (2): 44–50.
16. Fonjakin A.V. 2014. Sovremennye rekomendacii i perspektivy primenenija novyh peroral'nyh antikoaguljantov pri neklapannoj fibrilljacii predserdij [Current recommendations and prospects for the use of new oral anticoagulants in non-valvular atrial fibrillation]. Nevrologija, nejropsihiatrija, psihoso-matika. 4: 19–25.
17. Shubik Ju.V. 2014. Antitromboticheskaja terapija pri fibrilljacii predserdij: novye peroral'nye antikoaguljanty [Antithrombotic therapy for atrial fibrillation: new oral anticoagulants]. Medicinskij so-vet. 11: 38–48.
18. Craig T., Wann L.S. 2019. Guideline for the Management of Patients With Atrial Fibrillation. p. 52.
19. Eliquis (apixaban), package insert. Princeton, N.J.: Bristol-Myers Squibb; Dec, 2012.
20. Perzborn E., Roehrig S., Straub A., Kubitza D., Misselwitz F 2011. The discovery and devel-opment of rivaroxaban, an oral, direct factor Xa inhibitor. Nature reviews. 10: 61–75.
21. Pradaxa (dabigatran), package insert. Ridgefield, Conn.: Boehringer Ingelheim; Apr, 2013.
22. Xarelto (rivaroxaban), package insert. Titusville, N.J.: Janssen; Mar, 2013.